La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials

Identifieur interne : 000308 ( Istex/Curation ); précédent : 000307; suivant : 000309

Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials

Auteurs : Lorraine V. Kalia [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]

Source :

RBID : ISTEX:8E5F083D5F15E32FB9ACE93169C4835DB3C938FF

Abstract

Neurotransmitters other than dopamine are recognized as having modulatory roles within the basal ganglia and can influence the basal ganglia dopaminergic system to alter activity of the direct and indirect pathways. Many nondopaminergic neurotransmitter systems have been implicated in the mechanisms contributing to the motor features of Parkinson's disease (PD). Thus, it is now well established that neurotransmitter systems, including glutamatergic, GABAergic, cholinergic, noradrenergic, serotonergic, opioidergic, histaminergic, and adenosinergic systems, are affected in the pathogenesis of PD. Nondopaminergic neurotransmitter systems are thus targets for the development of novel therapies for motor symptoms and motor complications in PD. Over the last 5 years, more than 20 randomized, control trials (RCTs) in PD investigating drugs that target several of these nondopaminergic neurotransmitter systems for the treatment of motor features have been completed. There are at least 15 additional RCTs that are ongoing or planned. Here, we review these RCTs to highlight the potential nondopaminergic pharmacological therapies for treatment of motor features of PD. Nondopaminergic drugs are not expected to replace dopaminergic strategies, but further development of these drugs will likely yield novel approaches with positive clinical implications. © 2012 Movement Disorder Society

Url:
DOI: 10.1002/mds.25273

Links toward previous steps (curation, corpus...)


Links to Exploration step

ISTEX:8E5F083D5F15E32FB9ACE93169C4835DB3C938FF

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="no">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials</title>
<author>
<name sortKey="Kalia, Lorraine V" sort="Kalia, Lorraine V" uniqKey="Kalia L" first="Lorraine V." last="Kalia">Lorraine V. Kalia</name>
<affiliation wicri:level="1">
<mods:affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<mods:affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Toronto, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Toronto</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="1">
<mods:affiliation>Toronto Western Research Institute, Toronto Western Hospital, 399 Bathurst Street, Ontario, Toronto, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, 399 Bathurst Street, Ontario, Toronto</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation wicri:level="1">
<mods:affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<mods:affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Toronto, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Toronto</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<mods:affiliation>E-mail: sfox@uhnresearch.ca</mods:affiliation>
<country wicri:rule="url">Canada</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:8E5F083D5F15E32FB9ACE93169C4835DB3C938FF</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1002/mds.25273</idno>
<idno type="url">https://api-v5.istex.fr/document/8E5F083D5F15E32FB9ACE93169C4835DB3C938FF/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000308</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000308</idno>
<idno type="wicri:Area/Istex/Curation">000308</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<author>
<name sortKey="Kalia, Lorraine V" sort="Kalia, Lorraine V" uniqKey="Kalia L" first="Lorraine V." last="Kalia">Lorraine V. Kalia</name>
<affiliation wicri:level="1">
<mods:affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<mods:affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Toronto, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Toronto</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="1">
<mods:affiliation>Toronto Western Research Institute, Toronto Western Hospital, 399 Bathurst Street, Ontario, Toronto, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, 399 Bathurst Street, Ontario, Toronto</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation wicri:level="1">
<mods:affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<mods:affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Toronto, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Toronto</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<mods:affiliation>E-mail: sfox@uhnresearch.ca</mods:affiliation>
<country wicri:rule="url">Canada</country>
</affiliation>
</author>
</analytic>
<series>
<idno type="ISSN">0885-3185</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">Neurotransmitters other than dopamine are recognized as having modulatory roles within the basal ganglia and can influence the basal ganglia dopaminergic system to alter activity of the direct and indirect pathways. Many nondopaminergic neurotransmitter systems have been implicated in the mechanisms contributing to the motor features of Parkinson's disease (PD). Thus, it is now well established that neurotransmitter systems, including glutamatergic, GABAergic, cholinergic, noradrenergic, serotonergic, opioidergic, histaminergic, and adenosinergic systems, are affected in the pathogenesis of PD. Nondopaminergic neurotransmitter systems are thus targets for the development of novel therapies for motor symptoms and motor complications in PD. Over the last 5 years, more than 20 randomized, control trials (RCTs) in PD investigating drugs that target several of these nondopaminergic neurotransmitter systems for the treatment of motor features have been completed. There are at least 15 additional RCTs that are ongoing or planned. Here, we review these RCTs to highlight the potential nondopaminergic pharmacological therapies for treatment of motor features of PD. Nondopaminergic drugs are not expected to replace dopaminergic strategies, but further development of these drugs will likely yield novel approaches with positive clinical implications. © 2012 Movement Disorder Society</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000308 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000308 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Istex
   |étape=   Curation
   |type=    RBID
   |clé=     ISTEX:8E5F083D5F15E32FB9ACE93169C4835DB3C938FF
   |texte=   Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022